Skip to main content

Bone Infection

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
2 programs
1
Omadacycline PillPhase 21 trial
Clinical Priority Program-Bone Infection RegistryN/A1 trial
Active Trials
NCT01677000Completed297Est. Jun 2019
NCT05753215Active Not Recruiting180Est. Jun 2026
Paratek Pharmaceuticals
1 program
Omadacycline PillPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Innovation PharmaceuticalsOmadacycline Pill
Innovation PharmaceuticalsClinical Priority Program-Bone Infection Registry

Clinical Trials (2)

Total enrollment: 477 patients across 2 trials

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

Start: May 2023Est. completion: Jun 2026180 patients
Phase 2Active Not Recruiting
NCT01677000Innovation PharmaceuticalsClinical Priority Program-Bone Infection Registry

Clinical Priority Program-Bone Infection Registry

Start: Jun 2012Est. completion: Jun 2019297 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.